Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NKTRSAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase 1,600 shares of its common stock to one...
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
NKTRSAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NKTRSAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,310 shares of its common stock to two...
Nektar Therapeutics to Participate in Two Investor Conferences in September
NKTR(NASDAQ:NKTR) SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual...
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
NKTRSAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securities on June 30, 2025 were $175.9 million as compared to $269.1 million on December 31, 2024....
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
NKTRTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
NKTRNektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025
NKTRNektar Therapeutics Q1 EPS $(0.24) Misses $(0.16) Estimate, Sales $10.46M Miss $15.36M Estimate
NKTRNektar Therapeutics's Earnings: A Preview
NKTRAssessing Nektar Therapeutics: Insights From 5 Financial Analysts
NKTRJefferies Upgrades Nektar Therapeutics to Buy, Raises Price Target to $2
NKTRNektar Therapeutics: Files For Mixed Shelf Offering Of Up To $300M
NKTROppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $6 Price Target
NKTRAssessing Nektar Therapeutics: Insights From 4 Financial Analysts
NKTRHC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target
NKTRNektar Therapeutics Q4 2024 Adj. EPS $(0.15) Beats $(0.17) Estimate, Sales $29.200M Miss $29.860M Estimate
NKTRNektar Therapeutics Announces Completion Of Target Enrollment In REZOLVE-AA Phase 2b Clinical Trial Of Rezpegaldesleukin In Patients With Severe-to-Very Severe Alopecia Areata
NKTRHC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target
NKTRNektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes
NKTRHC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target
NKTRNektar Therapeutics Completes Target Enrollment In REZOLVE-AD Phase 2B Study Of Rezpegaldesleukin In Patients With Atopic Dermatitis
NKTRNektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflam
NKTRNektar Therapeutics To Sell Its Commercial PEGylation Reagent Manufacturing Business To Ampersand Capital Partners For $90M Total Consideration, Comprised Of $70M In Cash and $20M Equity Ownership In New Portfolio Company
NKTRPiper Sandler Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces Price Target of $7
NKTR